Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study
Circulation: Genomic and Precision Medicine · 2025-08 · 18 (4)
DOI: 10.1161/circgen.125.005103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025-08. Verfasst von Emil deGoma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tourmaline Bio, Inc, New York, NY (E.G., J.W.). Hauptthemen laut MEDLINE: Interleukin-6, Cardiovascular Diseases, Signal Transduction, Drug Development. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cardiovascular disease remains the leading cause of death worldwide, calling for the development of novel therapeutics. Over the past 3 decades, substantial investments in human genetic research have unveiled the genetic architecture of cardiovascular disease, offering promising novel therapeutic targets. These discoveries have been instrumental in the development of several cardiovascular drug development programs, such as those targeting proprotein convertase subtilisin/kexin type 9, lipoprotein (a), apo C 3 , and angiopoietin-like 3. Large-scale resources such as population-based biobanks and data repositories, now enable human genetic data to be leveraged at scale and inform not only target selection, but also clinical drug development. This review highlights the transformative potential of human genetics in cardiovascular drug development, focusing on IL (interleukin)-6 signaling as a case study. Specifically, we discuss how IL-6 signaling was pinpointed as a key causal mediator of atherosclerosis by genetic data, shaping the current development landscape for anti–IL-6 therapeutics in cardiovascular disease. Recent genetic studies employing innovative methodologies have provided key insights into prioritizing indications for clinical testing, informing repurposing strategies, optimizing clinical trial design for population selection, and assessing safety signals. Despite this progress, methodological challenges, such as pleiotropic effects of genetic variants, extrapolation of small genetic associations to large interventional effects, and the predominance of European-derived data, highlight the need for careful interpretation. Continued methodological advances, coupled with the emergence of high-throughput omics data and detailed cardiovascular phenotyping, promise unprecedented opportunities to refine drug discovery and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tourmaline Bio, Inc, New York, NY (E.G., J.W.).
- Institute for Stroke and Dementia Research (ISD), Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Germany (M.K.G.).
- Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA (M.K.G.).
- Munich Cluster for Systems Neurology (SyNergy), Germany (M.K.G.).
ORCID-Profile: John Walsh, Marios K Georgakis
Zitieren
APA
deGoma, E., Walsh, J., & Georgakis, M. K. (2025). Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study. Circulation: Genomic and Precision Medicine, 18(4). https://doi.org/10.1161/circgen.125.005103
Vancouver
deGoma E, Walsh J, Georgakis MK. Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study. Circulation: Genomic and Precision Medicine. 2025;18(4). doi:10.1161/circgen.125.005103
BibTeX
@article{deGoma2025,
author = {deGoma, Emil and Walsh, John and Georgakis, Marios K},
title = {Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study},
journal = {Circulation: Genomic and Precision Medicine},
year = {2025},
volume = {18},
number = {4},
doi = {10.1161/circgen.125.005103}
}
EUVIMED